Clinical • Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • GNAQ (G Protein Subunit Alpha Q) • HLA-A (Major Histocompatibility Complex, Class I, A) • MTAP (Methylthioadenosine Phosphorylase) • BAP1 (BRCA1 Associated Protein 1) • GNA11 (G Protein Subunit Alpha 11) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
PD-L1 expression • MSI-H/dMMR • PD-L1 overexpression • BRAF mutation • HLA-A*02
|
PD-L1 IHC 22C3 pharmDx
|
Kimmtrak (tebentafusp-tebn) • P-500